Aileron Therapeutics (NASDAQ:ALRN) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Thursday.
Separately, Zacks Investment Research upgraded shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 13th.
Shares of ALRN stock opened at $2.15 on Thursday. The firm has a market capitalization of $34.63 million, a price-to-earnings ratio of -1.21 and a beta of -0.64. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.10. Aileron Therapeutics has a one year low of $1.98 and a one year high of $12.96.
Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings results on Tuesday, August 7th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.04). As a group, equities research analysts predict that Aileron Therapeutics will post -2.34 earnings per share for the current fiscal year.
In other Aileron Therapeutics news, major shareholder Bioventures Ltd Novartis sold 20,388 shares of the stock in a transaction on Monday, August 20th. The shares were sold at an average price of $2.30, for a total value of $46,892.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders sold 56,962 shares of company stock valued at $131,638. Corporate insiders own 16.10% of the company’s stock.
A hedge fund recently bought a new stake in Aileron Therapeutics stock. Millennium Management LLC purchased a new stake in Aileron Therapeutics Inc (NASDAQ:ALRN) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 18,585 shares of the company’s stock, valued at approximately $151,000. Millennium Management LLC owned about 0.13% of Aileron Therapeutics at the end of the most recent reporting period. 6.05% of the stock is currently owned by hedge funds and other institutional investors.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Featured Story: Rule of 72
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.